BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

IgA nephropathy clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for IgA nephropathy: 74 (45 sponsors; 15 newly posted in the last 180 days, 1 stopped in the last 180 days; 7 new-entrant sponsors). Momentum score 26.4, rank 10 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 3, Phase 1 6, Phase 2 35, Phase 3 25, Phase 4 2, N/A 3.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Novartis Pharmaceuticals NVS12P3 7, P2 3, NA 210
Otsuka Pharmaceutical Development & Commercialization, Inc.4P3 3, P2 110
Alexion Pharmaceuticals, Inc.2P3 200
Vertex Pharmaceuticals Incorporated VERX new entrant2P3 220
Vera Therapeutics, Inc. VERA4P2 3, P3 100
Biogen BIIB2P3 1, P2 110
Biohaven Therapeutics Ltd. BHVN2P3 1, P1 110
Chengdu Suncadia Medicine Co., Ltd.2P3 1, P2 100
Haisco Pharmaceutical Group Co., Ltd.2P2 1, P3 111
Jade Biosciences, Inc. JBIO2P3 1, P2 110
Alpine Immune Sciences Inc, A Subsidiary of Vertex1P3 100
Biocity Biopharmaceutics Co., Ltd.1P3 101
Hoffmann-La Roche1P3 100
RemeGen Co., Ltd.1P3 100
Takeda TAK1P3 100
ADARx Pharmaceuticals, Inc. ADRX2P2 200
Keymed Biosciences Co.Ltd2P2 201
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.2P2 1, P1 101
Travere Therapeutics, Inc. TVTX2P2 1, P4 102
Triastek, lnc. new entrant2P1 222
Akebia Therapeutics AKBA1P2 100
Alpine Immune Sciences, Inc.1P2 100
argenx ARGX new entrant1P2 110
Asahi Kasei Therapeutics, AB1P4 101
Beijing Immunochina Medical Science & Technology Co., Ltd.1EARLY_P1 100

New-entrant sponsors: Vertex Pharmaceuticals Incorporated, Triastek, lnc., argenx.

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-05 est.P2Haisco Pharmaceutical Group Co., Ltd.NCT07616700 A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA NephropathyIgA Nephropathy (IgAN)recruiting73
2026-12-29 est.P2Suzhou Sanegene Bio Inc.NCT06786338 A Study of SGB-9768 in Patients With Complement-mediated Kidney DiseasesIgA Nephropathy (IgAN); C3 Glomerulopathy; IC-MPGNactive not recruiting45
2026-12-31 est.P3Biocity Biopharmaceutics Co., Ltd.NCT06819826 A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with ProteinuriaIgA Nephropathy (IgAN)recruiting360

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-09-22P2Vera Therapeutics, Inc. VERANCT07020923 Monthly Dosing of Atacicept in IgANIgA Nephropathy (IgAN); Berger Diseaseactive not recruiting90
2026-09 est.P2Nanjing Chia-tai Tianqing PharmaceuticalNCT06982040 Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA NephropathyPrimary IgA Nephropathynot yet recruiting80
2026-06-15 est.P2Wuhan Createrna Science and Technology Co., LtdNCT06687174 Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)IgA Nephropathy (IgAN)not yet recruiting72
2026-06-10P1/P2Novartis Pharmaceuticals NVSNCT03945318 Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)IgA Nephropathycompleted103
2026-06 est.P3RemeGen Co., Ltd.NCT05799287 A Study of Telitacicept for IgA Nephropathy (TELIGAN)Primary IgA Nephropathyactive not recruiting318

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "IgA nephropathy"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.